01. Historical Context
Bayer in context: what the current discount is actually pricing
At EUR 38.15 on May 15, 2026, Bayer is still a turnaround and litigation story, not a finished quality compounder. The share is down -43.8% from EUR 67.87 on May 31, 2016 and its monthly adjusted range over the last decade spans EUR 19.17 to EUR 89.06.
The latest operating data is better than the long chart suggests. Bayer reported FY2025 sales of EUR 46.6 billion, and in Q1 2026 sales rose to EUR 13.405 billion (+4.1% currency- and portfolio-adjusted), EBITDA before special items rose to EUR 4.453 billion (+9.0%), and core EPS improved to EUR 2.71 (+12.9%).
Even so, the stock is still being valued through the legal overhang. Reported FY2025 EPS was negative EUR 3.68, so a normal trailing P/E is not useful. Investors instead fall back on core EPS, where the stock trades around 8.3x on the latest full-year base and 8.3x to 9.3x forward.
| Horizon | What matters now | What would strengthen the thesis | What would weaken the thesis |
|---|---|---|---|
| Next 6 months | Guidance credibility, key events, and FX | Quarterly results keep beating the implied pace | Guidance slips or a major event turns negative |
| 12-24 months | Launch quality, cash conversion, and balance-sheet pressure | New products outgrow legacy drag | Cash flow or divisional execution weakens |
| To 2030 | Sustainable EPS compounding and the multiple investors will still pay | Execution proves durable enough to hold the valuation | Execution weakens and the market stops paying a premium |
02. Key Forces
Five forces that matter most from here
Bayer signed a three-year strategic AI collaboration with Cradle on January 7, 2026 to improve antibody discovery, and its Annual Report 2025 also highlights AI-led chemistry work through AgPlenus in Crop Science.
The second AI channel sits in Crop Science. If AI improves the hit rate for novel herbicides or shortens cycle time, it can add value beyond the current legal narrative.
Third, none of this yet changes the central valuation question. The stock still trades on legal risk, cash flow and confidence in divisional execution.
Fourth, AI matters most where it can raise returns on R&D and lower development waste.
Fifth, the market should resist a common mistake: assigning an AI premium to a stock whose main discount is legal.
| Factor | Current assessment | Bias | What would improve it | What would weaken it |
|---|---|---|---|---|
| Operating momentum | Latest quarter revenue was EUR 13.405 billion after FY2025 revenue of EUR 46.6 billion. | Mixed to constructive | Another quarter of volume and mix-driven growth | A guidance cut or weaker divisional mix |
| Earnings quality | Latest quarter core EPS was EUR 2.71. | Mixed | Cash conversion and margin stability | One-off items start masking softer underlying demand |
| Balance sheet / cash flow | The market wants proof that earnings translate into clean cash. | Bearish on legal overhang | Lower leverage or better free cash flow | More cash drain, debt pressure, or legal outflows |
| Valuation | The stock trades around 8.3x on the latest core earnings base and 8.3x to 9.3x forward by current assumptions. | Cheap | EPS upgrades without another multiple jump | Any sign the market already paid for perfection |
| Catalyst path | The operating case improved in Q1 2026 because Crop Science EBITDA before special items rose 17.9% to EUR 3.014 billion, but Pharmaceuticals still has to prove that launch assets can offset loss-of-exclusivity pressure. | Event-driven | Clear approvals, launches, or legal de-risking | A regulatory setback or delayed decision |
03. Countercase
What would break the thesis
Bayer's Annual Report 2025 says glyphosate provisions and liabilities totaled US$11.3 billion (EUR 9.6 billion) as of December 31, 2025, and management expects about EUR 5 billion of litigation payouts in 2026.
The second risk is that Q1 2026 may overstate operating momentum. Crop Science benefited from a soy licensing resolution and better seed performance, but Pharmaceuticals still has to deal with loss-of-exclusivity pressure. Q1 2026 free cash flow was minus EUR 2.320 billion.
Third, the share is cheap for a reason. A core multiple of only 8.3x looks attractive, but it is only cheap if the legal bill stops growing and if 2026 guidance actually translates into cleaner cash generation in 2027 and beyond.
Finally, macro matters through agriculture and rates. Bayer is more exposed than premium pharma peers to lower farmer sentiment, FX swings and a higher cost of capital.
| Risk | Current data point | Why it matters now | Review trigger |
|---|---|---|---|
| Glyphosate litigation | Provision and liabilities were US$11.3 billion (EUR 9.6 billion) at December 31, 2025. | That overhang still dominates free cash flow and investor confidence. | Supreme Court ruling expected by end-June 2026 and any settlement updates. |
| Cash flow strain | Q1 2026 free cash flow was minus EUR 2.320 billion. | Strong EBITDA does not help equity holders much if cash leaves through litigation and restructuring. | Watch Q2 and full-year free cash flow versus guidance. |
| Pharma execution | Q1 Pharma sales were roughly in line year on year while segment earnings fell. | A rerating needs proof that new launches can offset older-product pressure. | Re-check after each quarterly divisional update. |
| Valuation trap risk | The stock looks cheap at 8.3x to 9.3x forward core EPS, but reported FY2025 EPS was negative EUR 3.68. | Cheap valuation does not help if legal and cash-flow risk remain unresolved. | The setup improves only if cash generation normalizes after legal payments. |
04. Institutional Lens
What current institutional work adds to the analysis
The institutional and primary-source view on Bayer's AI work is encouraging but incomplete.
The company has real partnerships and real use cases, yet guidance for 2026 is still communicated in traditional terms: sales, EBITDA, core EPS and free cash flow.
The most credible investment takeaway is that AI can improve the long-run quality of Bayer's R&D portfolio, but it is not a substitute for legal resolution and cash-flow repair.
| Source | Latest update | What it said | Why it matters |
|---|---|---|---|
| Company results | May 12, 2026 | Latest quarter delivered revenue of EUR 13.405 billion and core EPS of EUR 2.71. | This is the cleanest read on whether the base case is intact. |
| Annual results | March 4, 2026 | FY2025 revenue was EUR 46.6 billion and the full-year earnings base was EUR 4.57 under the new 2026 methodology and EUR 4.91 under the old presentation core EPS with reported EPS of negative EUR 3.68. | It anchors valuation work and avoids projecting from a single quarter. |
| Company outlook | May 12, 2026 | Bayer confirmed on May 12, 2026 that currency-adjusted 2026 guidance still calls for EUR 45 billion to EUR 47 billion of sales and EUR 4.30 to EUR 4.80 of core EPS, while the FX-refreshed range is EUR 44.5 billion to EUR 46.5 billion of sales and EUR 4.10 to EUR 4.60 of core EPS. | This is the clearest public bridge from current operations to 2026 earnings power. |
| Reuters legal | April 27, 2026 | Reuters reported on April 27, 2026 that the U.S. Supreme Court appeared divided in Bayer's Roundup case and that a ruling is expected by the end of June 2026. Reuters also noted the outcome could influence the fate of more than 100,000 glyphosate-related claims. | This is the main public marker for the discount-rate shock that still dominates the stock. |
05. Scenarios
Scenario analysis investors can actually use
Base case, probability 50%: AI helps Bayer operate better, but the stock still follows something close to the broader EUR 40 to EUR 56 path because litigation and cash flow remain the dominant variables.
Bull case, probability 25%: AI improves development productivity enough in both Pharma and Crop Science that long-run normalized earnings rise, supporting the upper end of EUR 60 to EUR 82 once the legal discount narrows.
Bear case, probability 25%: AI stays strategically interesting but financially immaterial while legal costs keep dominating the equity narrative.
| Scenario | Probability | Stock implication | Measurable trigger | Review date | Suggested posture |
|---|---|---|---|---|---|
| AI creates operating upside | 25% | Could support the upper half of EUR 60 to EUR 82 | Visible evidence of faster candidate progression or better product economics | Annual R&D and divisional updates | Treat AI as optional upside only |
| AI remains a support function | 50% | Keeps the stock broadly in the EUR 40 to EUR 56 path | Guidance still dominated by ordinary operating metrics | Every annual report | Do not pay an AI premium before evidence appears |
| AI stays overshadowed | 25% | Stock can remain near EUR 22 to EUR 36 despite AI activity | Legal drag keeps overwhelming the operating narrative | Any year with renewed legal escalation | Focus on cash and legal outcomes first |
References
Sources
- Yahoo Finance chart data for Bayer (BAYN.DE), including latest price and 10-year monthly history
- Bayer Annual Report 2025
- Bayer Corporate Outlook in the Q1 2026 quarterly statement, published May 12, 2026
- Bayer Q1 2026 media update and guidance confirmation, May 12, 2026
- Reuters on Bayer's U.S. Supreme Court Roundup case, April 27, 2026
- Reuters on Bayer Q1 2026 operating profit, May 12, 2026
- IMF World Economic Outlook, April 2026
- Bayer-Cradle AI antibody discovery collaboration, January 7, 2026